Zydus Cadila's application for the emergency use authorization of its Covid-19 vaccine will likely be taken up by a Subject Expert Committee (SEC) of India's drug regulator this week, reported news agency Reuters, citing an Economic Times report.
According to the report, the rolling review of the vaccine has already been conducted. The company had last week submitted an application to the Drugs Controller General of India (DCGI), seeking authorisation for its ZyCoV-D three-dose vaccine.
It also submitted data evaluating a two-dose regimen for the shot. The SEC is now likely to compare the data and make a decision on its go-ahead.